Theralase Technologies (TSXV:TLT) Minority Interest : C$0.00 Mil (As of Dec. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Theralase Technologies Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Theralase Technologies's minority interest for the quarter that ended in Dec. 2024 was C$0.00 Mil.

Theralase Technologies Minority Interest Historical Data

The historical data trend for Theralase Technologies's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralase Technologies Minority Interest Chart

Theralase Technologies Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Minority Interest

Get a 7-Day Free Trial

Theralase Technologies Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Minority Interest	Get a 7-Day Free Trial															-	-	-	-	-

Theralase Technologies Minority Interest Calculation

Theralase Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (TSXV:TLT) » Definitions » Minority Interest

Comparable Companies

Traded in Other Exchanges

TLTFF:USA TTX:Germany

Address

41 Hollinger Road, Toronto, ON, CAN, M4B 3G4

Website

https://www.theralase.com

Theralase Technologies Inc is a clinical-stage pharmaceutical company. It is dedicated to the research and development of light-activated Photo Dynamic Compounds, their associated drug formulations, and technology platforms intended to safely and effectively; treat various cancers, bacteria, and viruses. The Cool Laser Technology division designs, develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle, and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.

Executives

Matthew Thomas Perraton	Director
Roger John Dumoulin-white	10% Security Holder, Director, Senior Officer
Kristina Maria Hachey	Senior Officer
Arkady Mandel	Senior Officer
Guy John Anderson	Director
Shawn Shirazi	Senior Officer